| Literature DB >> 34345431 |
Selladurai Pirasath1, Chandrakulasegeran Athirayan1, Dilani Gajan1.
Abstract
The saw-scaled viper (Echis carinatus) is considered as a highly venomous snake in Sri Lanka. The clinical manifestations are localized pain and swelling, coagulopathy and renal impairment. Thrombotic microangiopathy is rarely reported as a complication of saw-scaled viper envenoming. The clinical manifestations of thrombotic microangiopathy include thrombocytopenia, microangiopathic haemolytic anaemia and acute kidney injury. The consumption coagulopathy of post-envenoming could be followed by a syndrome consistent with thrombotic microangiopathy. We describe a patient with thrombotic microangiopathy following saw-scaled viper systemic envenoming which was managed with antivenom and supportive therapy. The dead snake which was brought by patient was identified by medical professional as saw-scaled viper (E. carinatus) based on morphological features. This case illustrates a rare manifestation thrombotic microangiopathy following saw-scaled viper envenoming.Entities:
Keywords: Saw-scaled viper; acute kidney injury; microangiopathic haemolytic anaemia; thrombocytopenia; thrombotic microangiopathy
Year: 2021 PMID: 34345431 PMCID: PMC8283212 DOI: 10.1177/2050313X211032399
Source DB: PubMed Journal: SAGE Open Med Case Rep ISSN: 2050-313X
Figure 1.The dead specimen of saw-scaled viper (SSV) (Echis carinatus) which was brought by patient.
The investigation profile of patient is shown with clinical progression of disease.
| Investigation profile | Day | ||||||
|---|---|---|---|---|---|---|---|
| Admission | 12 h | 24 h | Day 2 | Day 3 | Day 5 | Day 7 | |
| Complete blood count | |||||||
| White cell count (4000–11,000/mm3) | 14,800 | 13,800 | 12,000 | 14,000 | 12,000 | 11,000 | 6840 |
| Neutrophils (50%–70%) | 50 | 89 | 80 | 74 | 70 | 72 | 56 |
| Lymphocytes (20%–40%) | 37 | 4 | 14 | 10 | 19 | 19 | 36 |
| Haemoglobin (12–16 g/dL) | 13.7 | 12.0 | 10.0 | 10.0 | 10.4 | 12.0 | 13.1 |
| MCV (80–100 fL) | 78 | 84 | 91 | 90 | 90 | 89 | 86 |
| Red cell count (400,000–550,00 mm3) | 480,000 | 400,000 | 341,000 | 310,000 | 307,000 | 334,000 | 410,000 |
| Platelets (150,000–450,000 mm3) | 287,000 | 154,000 | 131,000 | 92,000 | 130,000 | 145,000 | 210,000 |
| Renal functions tests | |||||||
| Blood urea (18–55 mg/dL) | 44 | 55 | 75 | 60 | 55 | 45 | 32 |
| Serum creatinine (0.7–1.5 mg/dL) | 1.2 | 2.1 | 3.1 | 2.7 | 1.8 | 1.7 | 1.1 |
| Serum electrolytes | |||||||
| Serum sodium (135–145 mmol/L) | 135 | 135 | 138 | 138 | 134 | 137 | 135 |
| Serum potassium (3.5–5.0 mmol/L) | 4.1 | 4.7 | 5.1 | 5.6 | 4.8 | 4.2 | 3.9 |
| Liver profile | |||||||
| Serum AST (0–45 U/L) | 24 | 48 | 54 | 72 | 60 | 48 | 40 |
| Serum ALT (0–35 U/L) | 28 | 40 | 48 | 58 | 42 | 34 | 38 |
| Total bilirubin (0–2.0 mg/dL) | 1.1 | 1.8 | 2.8 | 2.4 | 1.5 | 1.3 | 1.0 |
| Indirect bilirubin (0–1.6 mg/dL) | 0.8 | 1.2 | 1.9 | 1.8 | 0.9 | 0.8 | 0.8 |
| Clotting profile | |||||||
| PT/INR (<1.4) | >12 | 1.2 | 1.2 | 1.0 | 1.1 | 1.2 | |
| APTT (<35 s) | >128 | 32 | 32 | 34 | 32 | 35 | |
| Urine full report | Nil | – | Nil | – | – | Nil | |
| Protein (+) | 1.2 | – | 3–4 | – | – | 3–5 | |
| Pus cells (/HPF) | 10–15 | – | 5–10 | – | – | 5–10 | |
| Red cells (/HPF) | Nil | _ | Nil | – | Nil | ||
| Active sediment (+) | |||||||
| Serum CPK level | – | 1051 | – | 325 | – | 243 | 109 |
MCV: Mean Corpuscular Volume; AST: Asparate transaminase; ALT: Alanine transaminase; PT/INR: Prothrombin time/International normalized Ratio; HPF: High PowerField; CPK: Creatinine Phosphokinase.